Ascendis Pharma A/S / Fundamentals
Income statement
- Net revenue
€490.75M - Cost of goods sold
€74.19M - Gross profit
€416.56M - SG&A expenses
€353.67M - R&D expenses
€311.43M - EBITDA
-€155.48M - D&A
€10.49M - EBIT
-€253.52M - Interest expenses
€103.15M - EBT
-€264.13M - Tax expenses
€7.01M - Net income
-€271.15M
Cash flow statement
- Net deferred tax
€5.95M - Non-cash items
-€43.66M - Changes in working capital
€18.42M - Operating cash flow
-€164.96M - Capex
€5.93M - Other investing cash flow
€0.00 - Net investing cash flow
-€5.93M - Total cash dividends paid
€0.00 - Issuance of common stock
€19.29M - Debt repayment
€119.85M - Other financing cash flow
€306.57M - Net financing cash flow
€416.92M - Foreign exchange effects
-€10.68M - Net change in cash
€235.35M - Cash at end of period
€494.05M - Free cash flow
-€159.03M
Balance sheet
- Cash and cash equivalents
€494.05M - Cash and short-term investments
€494.05M - Total receivables
€110.45M - Inventory
€303.38M - Other current assets
€45.08M - Total current assets
€952.96M - Property, plant & equipment
€93.54M - Goodwill
€0.00 - Intangible assets
€3.79M - Long-term investments
€34.90M - Other non-current assets
€2.71M - Total non-current assets
€134.95M - Total assets
€1.09B - Accounts payable
€93.72M - Short-term debt
€462.35M - Other current liabilities
€378.93M - Total current liabilities
€935.00M - Long-term debt
€330.19M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€10.29M - Total non-current liabilities
€340.47M - Total liabilities
€1.28B - Common stock
€8.21M - Retained earnings
-€2.67B - Other equity
€309.00K - Total equity
-€187.57M - Total liabilities and shareholders' equity
€1.09B
Company information
- Market capitalization
€8.87B - Employees
1K - Enterprise Value
€9.25B
Company ratios
- Gross margin
-
84.9% Much better than peer group: -61,333,590,109,526.3% - EBITDA margin
-
-31.7% Much better than peer group: -337,253,183,772,469.2% - EBIT margin
-
-51.7% Much better than peer group: -340,401,581,280,916.0% - EBT margin
-
-53.8% Much better than peer group: -339,997,634,307,327.6% - Net margin
-
-55.3% Much better than peer group: -339,997,634,307,152.5% - ROE
-
144.6% Much better than peer group: -54.9% - ROA
-
-24.9% Much better than peer group: -45.2% - Asset turnover
-
45.1% Much better than peer group: 15.3% - FCF margin
-
-34.8% Much better than peer group: -283,292,454,799,099.3% - FCF yield
-1.9% - Efficiency ratio
131.7% - Net sales per employee
-
€482.54K - Net income per employee
-
-€266.62K